#South Korea #Seoul #Cancer Research #Lunit SCOPE #SITC

Lunit Partners with SITC for Innovative Cancer Research Program

Lunit, a prominent player in AI-driven cancer diagnostics, has announced a strategic partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration aims to empower SITC members by providing them access to Lunit SCOPE® IO, an innovative tool designed for in-depth analysis of tumor microenvironments (TME) using advanced artificial intelligence technologies.

This exclusive research program allows researchers affiliated with SITC, a leading organization dedicated to advancing cancer immunotherapy, to utilize Lunit's powerful AI model at no cost. By facilitating quantitative immune phenotyping and TME analysis from hematoxylin and eosin (HE) whole slide images, this initiative is set to provide unprecedented insights into cancer biology that could significantly enhance immunotherapy outcomes.

Key Features of the Program

The initiative provides the following features that stand to greatly benefit academic and non-profit researchers:
1. Quantitative Immune Phenotyping: It can classify the tumor microenvironment into inflamed, excluded, and desert types, enabling actionable insights for tailored immunotherapy strategies.
2. TIL Analysis: The program helps in identifying and quantifying tumor-infiltrating lymphocytes (TILs), crucial biomarkers for immune response in cancer treatment.
3. Comprehensive TME Profiling: Researchers gain access to analyze various histological features, including the identities and roles of stromal cells like fibroblasts and macrophages, which are vital in understanding tumor biology.
4. Support for Novel Biomarker Discovery: By facilitating the identification of new biomarkers, the program opens avenues for developing predictive models of therapeutic responses.

Lunit SCOPE IO stands out by bridging the gap between traditional pathology and modern precision oncology, making it a powerful tool in the ongoing quest to improve cancer treatment strategies. By utilizing deep learning algorithms, Lunit can yield meticulous quantifications of immune responses, which have become imperative in designing effective therapy plans.

Eligibility and Application Process

The Lunit Research Program is available for SITC members who are affiliated with academic or non-profit research institutions. Eligible researchers include faculty members, research scientists, and postdoctoral fellows with expertise in oncology, pathology, or immunology. To apply, members must submit a brief study outline and the principal investigator's CV. The application period for this initiative spans from February 1 to April 30, with a review phase expected to last 2-3 months.

Important Dates

• - Application Period: February 1 – April 30, 2025
• - Review Process: May – July 2025
• - Project Initiation: Summer 2025

Impact of the Partnership

Brandon Suh, CEO of Lunit, expressed excitement about the partnership, highlighting that it will allow researchers to explore the advanced capabilities of Lunit SCOPE IO to deepen the understanding of the tumor microenvironment.

Mary Dean, Executive Director of SITC, reiterated the importance of this initiative in supporting impactful cancer research and innovation, stating, "For forty years, SITC has been promoting the field of immuno-oncology, and this partnership aligns perfectly with our mission to enhance patient outcomes."

Overall, the collaboration between Lunit and SITC marks a significant advancement in immunotherapy research, promising to unlock new potential for precise cancer treatments tailored to individual patient needs. With access to state-of-the-art AI tools, researchers will be well-equipped to contribute to the evolving landscape of cancer therapy.

For more information regarding this program, interested parties can reach out to Dr. Siraj Ali via email.

About Lunit

Founded in 2013, Lunit is dedicated to combating cancer through the application of AI technology in medical image analysis, with a strong focus on ensuring accurate diagnostics and optimal treatment plans.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer is committed to improving patient outcomes through research into cancer immunology and therapeutic strategies, solidifying their role as leaders in the field.